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FROM BONE MARROW TO BRAIN: STEM CELLS IN NEUROPROTECTION, 
PLASTICITY, AND NEUROREGENERATION
Milena Penkowa 
Section of Neuroprotection, Sommerstedgade, Copenhagen, Denmark
At present, curative therapies for neurological diseases are limited, even though they are prevalent worldwide. So far, molecular 
strategies developed for brain disorders act through one single molecular mechanism, yet, these diseases are multifactorial and 
highly complex, as to why a successful therapy likely calls for a more multifaceted and cell-based approach. The bone marrow 
contains a mixed stem and progenitor cell population including hematopoietic stem cells (HSC) and mesenchymal stromal stem 
cells (MSC), which are potential endogenous candidates for cell-based therapy in various brain disorders like stroke, trauma, 
and neurodegeneration. Unlike the neural stem cells (NSC), bone marrow HSC are readily isolated, mobilized and expanded by 
means of treatment with granulocyte-colony stimulating factor (G-CSF) and CXCR4-antagonist plerixafor. Once in the blood 
circulation, the cells preferentially home to injured tissues including the brain.  Bone marrow cells may convey neuroprotection, 
plasticity, and neuroregeneration by different mechanisms of action, which include either transdifferentiation or cell-cell fusion 
with resident brain cells. Bone marrow cells also benefit the injured brain by secreting bioactive factors, which in a paracrine 
manner convey intrinsic repair and enhance neurogenesis. Furthermore, transplanted MSC may activate the astrocytes leading 
to increased glial secretion of neurotrophic growth factors and enhanced proliferation and migration of the resident NSC. These 
neuroregenerative mechanisms of action are not mutually exclusive, in fact they may provide a multifaceted therapeutic ap-
proach, which is requested in order to move neurorestorative and protective strategies into the clinic. Biomed Rev 2011; 22: 1-6.
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INTRODUCTION: STEM CELLS IN BRAIN
In animal and human central nervous system (CNS), neurons are 
generated in intracerebral germinal zones such as the subven-
tricular zone (SVZ) and the dentate gyrus (DG) of hippocam-
pus (1-3). Inside the germinal zones, neural stem cells (NSC) 
proliferate and migrate in response to brain injury and various 
pathological conditions including: inflammation, degenera-
tion and ischemia (2,4-6). However, in the adult human brain, 
significant neurogenic activity and NSC recruitment from the 
germinal zones to an injured area remain controversial (1,3). 
While some groups report NSC and their proliferative capacity 
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intact in the human parkinsonian brain as compared to those of 
human adult controls (3), others suggest that proliferating and 
migrating NSC are abundant in the human brain only before 
18 months of age, after which the neurogenic capacity subsides 
and by adulthood, it is almost extinct (1). Other limitations in 
neurogenesis include that the differentiation of endogenous NSC 
might be restricted to glial cell types (2,7). 
To address some of these hurdles, NSC activation in SVZ 
and DG as well as their regulation and recruitment have been 
extensively studied in experimental studies (2,5-7). Even if 
adult neurogenesis can provide neuroregeneration after some 
types of acquired brain injuries (5,6), this approach remains 
controversial, since the NSC found in brains from e.g. patients 
suffering Alzheimer’s Disease (AD) were demonstrated to be 
implicated in AD pathogenesis (8). Particularly, NSC in the 
adult human brain were reported to generate aneuploid cells, 
characteristic for histopathology of neurodegenerative disorders 
(8,9). Accordingly, the therapeutic use of human endogenous 
NSC for neurodegenerative diseases, in particular AD remains 
contentious and not yet realistic. It is needed to reconsider the 
current stem cell-based concepts and their therapeutic applica-
tion in neuroregenerative medicine as well as to investigate 
non-NSC-derived stem cell sources. For this purpose, stem and/
or progenitor cells derived from other tissues than the brain, 
such as the bone marrow, could prove suitable. Bone marrow-
derived stem and progenitor cells offer significant advantages 
over resident NSC in the diseased brain, since they are: 1. devoid 
of intrinsic cellular dysfunctions relating to neurodegenerative 
disorders; 2. easily obtained, expanded, and mobilized from 
host bone marrow into blood; 3. show preferential homing to 
the inflamed brain; 4. able to cross the blood-brain barrier due 
to chemotactic migration; and 5. interact with resident neuroglia 
and the neural micromilieu leading to improved neuroplasticity, 
repair and functional recovery (8-13). Significant crosstalks 
between the nervous and hematopoietic systems might involve 
the CNS’ neuroendocrine regulation of host immune responses 
(13), although the possible neurotherapeutic use of bone marrow 
in CNS pathologies is still not completely elucidated.
This review highlights the recent and major findings in the 
field of neuroregeneration by means of recruitment of non-
neural cells from the bone marrow. It summarizes the putative 
mechanisms of actions comprising 1. cellular replacement 
by putative transdifferentiation, 2. cell-cell fusion leading 
to hybrid brain cells, 3. indirect signalling through activated 
astroglia, and 4. paracrine secretion of neurotrophic growth 
factors supporting neuronal survival and brain repair.
STEM CELLS FROM BONE MARROW TO BRAIN
In the adult bone marrow reside multipotent and easily 
mobilized stem cells. Accumulating data support the obser-
vation that bone marrow-derived hematopoietic and non-
hematopoietic stem cells transdifferentiate into cell types of 
different tissues including glia and neurons (2,10-15). This 
degree of plasticity, self-renewal, and pluripotency with the 
ability to undergo neurodifferentiation is a hallmark of bone 
marrow-derived stem cells, although the same wide-ranging 
neuroplasticity can be found in a range of other stem cell 
lineages such as adipose-derived stem cells (16). The ‘cell 
replacement’ concept is likely not the only therapeutic mecha-
nism provided by stem cells. Accumulating data have shown 
that expression and paracrine secretion of neurotrophic factors 
from bone marrow-derived stem cells also provide support for 
neuronal survival, intrinsic brain repair, and neuroregenera-
tive processes (10,17,18). These mechanisms open up new 
possibilities regarding the neurotherapeutic use of mobilized 
stem cells from the bone marrow. 
Advantage of the bone marrow stem cells
As compared to other stem cell lineages, the bone marrow-
derived CD34+ hematopoietic stem cells (HSC) possess a 
major advantage as compared to other stem cell types, as the 
HSC are easily expanded and mobilized endogenously leading 
to their blood-borne circulation, from which these cells are 
particularly able to home to injured or inflamed tissues in any 
compartment of the human body including the CNS (17-22). 
The damaged brain displays high levels of chemokines like 
stromal cell-derived factor-1 (SDF-1), which attract circulat-
ing HSC, due to their surface expression of CXC-chemokine 
receptor-4 (CXCR4; also known as fusin or CD184) 
(10,14,15,17-21). In the bone marrow, stromal expression 
of SDF-1 that binds CXCR4 on HSC is a key factor in HSC 
residency (2,14,15,18-20). However, by means of granulocyte 
colony-stimulating factor (G-CSF) combined with synergistic 
agent plerixafor (a rapidly degraded, reversible CXCR4 an-
tagonist), hypermobilization of endogenous CD34+ HSC into 
the circulation is obtained (13-15,17-20,23). After HSC egress 
to the circulation, the HSC home to the injured brain by means 
of increased neuroglial expression of SDF-1 (14,15,18-23). 
Accordingly, CD34+ cells are recruited in significant num-
bers to the injured brain (17,22). Both recruitment to injured 
or inflamed brain as well as their homing to a depleted bone 
marrow are characteristic for HSC and combined with their 
feasible G-CSF/plerixafor-mobilization, these cells are highly 
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Figure 1. Illustration of the bone marrow, blood, and brain tissues. CXCR4+ HSC are anchored to SDF-1+ stromal cells of the 
bone marrow. The administration of G-CSF combined with CXCR4-antagonist plerixafor leads to hypermobilization of endog-
enous HSC into the blood circulation along with stimulation of neutrophilic granulocytes. The blood-borne HSC are recruited 
to the injured brain by chemotaxis. Inside CNS, bone marrow cells improve neuroprotection, plasticity, and brain repair.
suitable for regenerative medicine. Moreover, since this ap-
proach allows a strictly endogenous strategy, the well-known 
ethical, technical and biological problems relating to allogenic 
and donor-based approaches are bypassed.
Neuroregenerative mechanisms of action
As reviewed here, various independent researchers have 
reported that bone marrow-derived subpopulations of stem 
cells can generate neural cell types both in vitro and in vivo 
(2,25-29).
Hence, in mice without the capacity to generate myeloid and 
lymphoid cell lineages, administration of adult bone marrow 
resulted in transformation of the transplanted cells into neu-
ronal phenotypes expressing neuron-specific antigens (25,27). 
Thus, by receiving male bone marrow-derived cells, female 
recipient mice displayed Y chromosome in neurons dispersed 
throughout their female brain (27). Likewise, olfactory bulb 
neurons contained bone marrow-derived graft cells as dem-
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onstrated due to the genetic alteration of the transplants (25).
Moreover, bone marrow-derived MSC may in vivo adopt 
both neuronal phenotype and functions as shown in a study 
of transplanted bone marrow cells including their migration, 
phenotypic expression, and long-term survival in rats (2,28). 
Consequently, bone marrow-derived cells contain the capabil-
ity to transform into CNS cell types that are viable within the 
microenvironment. Also, the cell grafts are likely differentiated 
into neural phenotypes as they express both markers of neural 
progenitors as well as mature neuronal markers such as e.g. 
neuronal-specific nuclear (NeuN) protein (2,28). In an interest-
ing study, adult human bone marrow cells were demonstrated 
to give rise to adult human brain cells, as shown in cerebel-
lum from patients, who suffered from malignant hematologic 
neoplasms for which they received radiation, chemotherapy, 
and bone marrow transplantation (29). In the Purkinje neurons 
of female patients receiving male bone marrow transplants, 
both an X and a Y chromosome were detected in the nuclei, 
which indicates that male donor cells had infiltrated the CNS, 
in which they either transdifferentiated into Purkinje neurons 
or fused with the host cerebellar cells (29).
In favor of the cell fusion concept are studies that have 
verified how co-culturing of embryonic stem cells with bone 
marrow-derived stem cells results in cellular fusion (30,31). 
Likewise, co-culturing of murine brain cells with embryonic 
pluripotent cells led to a spontaneous formation of hybrid cells 
due to cellular fusion (32). Accordingly, spontaneous fusion of 
cells may likely provide an explanation for the reported ‘cell 
fate-switches’ or the apparent “transdifferentiation” observa-
tions, which otherwise have been attributed to pluripotency and 
plasticity of stem cells (30,32). In line with this, it was shown 
that cell-cell fusion of donor and recipient cells is responsible 
for the regeneration of normal hepatic function and structure 
after bone marrow transplants in mice (33-35).
However, it is unlikely that this mechanism of cell-cell 
fusion is going to reduce the excitement relating to stem cell 
pluripotential properties and cell-based treatment strategies. 
Hence, formation of hybrid cells due to spontaneously fused 
bone marrow and resident cells is a process considered im-
portant within the field of stem cell therapy and regenerative 
medicine (33-35).The fusion of cells as a mechanism of cell 
replacement may however seem discouraging compared to 
the concept of transdifferentiation, where bone marrow stem 
cells are considered to undergo steps of de- and transdiffer-
entiation into functionally complete neurons. However, bone 
marrow cell fusion in the CNS may in fact provide unpredicted 
advantages by endowing damaged or pre-apoptotic neurons 
with intact genes and gene regulatory machinery. Since it is not 
easy to reproduce de novo and appropriately replace the adult 
brain’s highly specialized neurons and their neural networks, 
the fusion-mediated cell resuscitation could provide a quite 
compliant practice. Nevertheless, in vitro studies have demon-
strated that bone marrow stem cells are capable of undergoing 
complete and functional transdifferentiation into neurons, and 
in these cell culture experiments, fusion mechanisms can be 
ruled out, since no co-culturing with other neuronal cell types 
was applied (2,10-15,25-29). In addition to the cell replace-
ment mechanisms, the neurotrophic growth support mediated 
by bioactive factors secreted in a paracrine manner by stem 
cells may cause more significant and immediate treatment ef-
fects in the injured CNS (18). In fact, transplantation of bone 
marrow stem cells results in surprisingly low survival rates of 
the engrafted cells inside the brain tissue (10,17).
Among the bioactive factors secreted by bone marrow 
cells are brain-derived neurotrophic factor (BDNF), vascular 
endothelial growth factor (VEGF), basic fibroblast growth 
factor (bFGF, FGF-2), nerve growth factor (NGF), and insu-
lin-like growth factor-1 (IGF-1), which all are demonstrated 
to exert profound neuroprotective and neuroregenerative 
actions including the stimulation of both intrinsic neurogen-
esis and angiogenesis in the CNS (10,17,18,36,37). Another 
indirect molecular mechanism of action might convey the 
neuroprotective and -regenerative effects in the CNS of 
administered bone marrow. Hence, in a recent study it was 
shown that transplanted bone marrow MSC can activate 
resident astroglia in the ischemic brain leading to increased 
astrocytic secretion of glial cell derived neurotrophic factor 
(GDNF), which in the CNS promotes plasticity and recovery 
(36,37). Hence, the increased astroglial GDNF levels led to 
enhanced proliferation and migration of the resident NSC in 
the ischemic brain (37). 
Reactive astroglia have several neuroprotective and 
regenerative actions in the brain and are the main source 
of neurotrophic growth factors, antioxidants, and neuronal 
survival signals as well as an astrocytic phenotype provides 
the endogenous source of NSC within the brain (36,38). 
Consequently, the study of transplanted MSC effects upon 
astroglia during brain ischemia (37) is fundamental, as it re-
veals how stem cell-based therapy may not only work through 
cellular replacement and/or cellular fusion. Hence, a range of 
molecular and/or paracrine mechanisms are likely contribut-
ing to the neurotherapeutic effects of bone marrow cells and 
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these involve secretion of bioactive factors, signal transduction 
mechanisms, extracellular cross-talking, and repair through 
activation of astroglia. 
CONCLUSION
As reviewed here, the neurotherapeutic use of bone marrow-
derived cells in brain injury and diseases has opened up new 
avenues of stem cell-based insight and treatment. Moreover, 
we will likely see in the near future that there are more options 
in terms of the different possibilities regarding how to apply 
which types of stem cells and/or their molecular repertoire in 
terms of secreted bioactive factors. Further elucidation of the 
diverse biological mechanisms by which various stem cells 
may exert neuroprotective, restorative and neuroregenerative 
functions will most likely result in the discovery of new and 
safer neurotherapies that can be applied in the clinic.
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